Surrozen (NASDAQ:SRZN) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Surrozen (NASDAQ:SRZN) in a report published on Thursday, Marketbeat reports. The brokerage issued an overweight rating and a $40.00 price objective on the stock.

Other equities analysts have also recently issued research reports about the company. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. Wall Street Zen upgraded Surrozen to a “sell” rating in a research note on Friday, November 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $36.00.

Surrozen Price Performance

Surrozen stock opened at $26.59 on Thursday. The firm has a market capitalization of $227.88 million, a P/E ratio of -1.19 and a beta of 0.58. Surrozen has a 52-week low of $5.90 and a 52-week high of $27.96. The stock has a fifty day moving average price of $21.84 and a two-hundred day moving average price of $16.33.

Insider Transactions at Surrozen

In other Surrozen news, major shareholder Group Gp Lp Column III bought 30,884 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were acquired at an average cost of $19.54 per share, with a total value of $603,473.36. Following the acquisition, the insider owned 981,890 shares of the company’s stock, valued at $19,186,130.60. The trade was a 3.25% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Tim Kutzkey purchased 30,884 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The stock was acquired at an average price of $19.54 per share, for a total transaction of $603,473.36. Following the purchase, the director owned 981,890 shares in the company, valued at $19,186,130.60. This trade represents a 3.25% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders acquired 231,713 shares of company stock worth $4,635,485. 45.18% of the stock is owned by company insiders.

Institutional Trading of Surrozen

Hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Surrozen by 50.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after buying an additional 500 shares during the period. Persistent Asset Partners Ltd acquired a new stake in Surrozen during the fourth quarter worth approximately $99,000. Citadel Advisors LLC boosted its holdings in shares of Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after acquiring an additional 3,424 shares during the period. Marshall Wace LLP acquired a new position in shares of Surrozen in the fourth quarter valued at approximately $247,000. Finally, Geode Capital Management LLC grew its position in shares of Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after purchasing an additional 5,702 shares during the last quarter. Institutional investors and hedge funds own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.